Earnings Reportpositive

Earnings Report

Other upcoming events for IMCR

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Earnings Report — IMCR Earnings Report | BioSniper